Skip to main content
Top
Published in: BMC Infectious Diseases 1/2002

Open Access 01-12-2002 | Research article

Smoking, season, and detection of chlamydia pneumoniaeDNA in clinically stable COPD patients

Authors: Marek Smieja, Richard Leigh, Astrid Petrich, Sylvia Chong, Dennis Kamada, Frederick E Hargreave, Charles H Goldsmith, Max Chernesky, James B Mahony

Published in: BMC Infectious Diseases | Issue 1/2002

Login to get access

Abstract

Background

The prevalence and role of Chlamydia pneumoniae in chronic obstructive pulmonary disease (COPD) remain unclear.

Methods

Peripheral blood mononuclear cells were obtained from 100 outpatients with smoking-related, clinically stable COPD, and induced sputum was obtained in 62 patients.

Results

Patients had mean age (standard deviation) of 65.8 (10.7) years, mean forced expiratory volume in one second of 1.34 (0.61) L, and 61 (61.0%) were male. C. pneumoniae nucleic acids were detected by nested polymerase chain reaction in 27 (27.0%). Current smoking (odds ratio {OR} = 2.6, 95% confidence interval {CI}: 1.1, 6.6, P = 0.04), season (November to April) (OR = 3.6, 95% CI: 1.4, 9.2, P = 0.007), and chronic sputum production (OR = 6.4, 95% CI: 1.8, 23.2, P = 0.005) were associated with detection of C. pneumoniae DNA.

Conclusions

Prospective studies are needed to examine the role of C. pneumoniae nucleic acid detection in COPD disease symptoms and progression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Barnes PJ: Chronic obstructive pulmonary disease. N Engl J Med. 2000, 343 (4): 269-280. 10.1056/NEJM200007273430407.CrossRefPubMed Barnes PJ: Chronic obstructive pulmonary disease. N Engl J Med. 2000, 343 (4): 269-280. 10.1056/NEJM200007273430407.CrossRefPubMed
2.
go back to reference Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997, 349 (9064): 1498-1504. 10.1016/S0140-6736(96)07492-2.CrossRefPubMed Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997, 349 (9064): 1498-1504. 10.1016/S0140-6736(96)07492-2.CrossRefPubMed
3.
go back to reference Sethi JM, Rochester CL: Smoking and chronic obstructive pulmonary disease. Clin Chest Med. 2000, 21 (1): 67-86.CrossRefPubMed Sethi JM, Rochester CL: Smoking and chronic obstructive pulmonary disease. Clin Chest Med. 2000, 21 (1): 67-86.CrossRefPubMed
4.
go back to reference Thom DH, Grayston JT, Campbell LA, Kuo CC, Diwan VK, Wang SP: Respiratory infection with Chlamydia pneumoniae in middle-aged and older adult outpatients. Eur J Clin Microbiol Infect Dis. 1994, 13 (10): 785-792.CrossRefPubMed Thom DH, Grayston JT, Campbell LA, Kuo CC, Diwan VK, Wang SP: Respiratory infection with Chlamydia pneumoniae in middle-aged and older adult outpatients. Eur J Clin Microbiol Infect Dis. 1994, 13 (10): 785-792.CrossRefPubMed
5.
go back to reference Blasi F, Legnani D, Lombardo VM, Negretto GG, Magliano E, Pozzoli R, et al: Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J. 1993, 6 (1): 19-22.PubMed Blasi F, Legnani D, Lombardo VM, Negretto GG, Magliano E, Pozzoli R, et al: Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J. 1993, 6 (1): 19-22.PubMed
6.
go back to reference Miyashita N, Niki Y, Nakajima M, Kawane H, Matsushima T: Chlamydia pneumoniae infection in patients with diffuse panbronchiolitis and COPD. Chest. 1998, 114 (4): 969-971.CrossRefPubMed Miyashita N, Niki Y, Nakajima M, Kawane H, Matsushima T: Chlamydia pneumoniae infection in patients with diffuse panbronchiolitis and COPD. Chest. 1998, 114 (4): 969-971.CrossRefPubMed
7.
go back to reference Von Hertzen L, Isoaho R, Leinonen M, Koskinen R, Laippala P, Toyryla M, et al: Chlamydia pneumoniae antibodies in chronic obstructive pulmonary disease. Int J Epidemiol. 1996, 25 (3): 658-664.CrossRefPubMed Von Hertzen L, Isoaho R, Leinonen M, Koskinen R, Laippala P, Toyryla M, et al: Chlamydia pneumoniae antibodies in chronic obstructive pulmonary disease. Int J Epidemiol. 1996, 25 (3): 658-664.CrossRefPubMed
8.
go back to reference Von Hertzen L, Alakarppa H, Koskinen R, Liippo K, Surcel HM, Leinonen M, et al: Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. Epidemiol Infect. 1997, 118 (2): 155-164. 10.1017/S095026889600725X.CrossRefPubMedPubMedCentral Von Hertzen L, Alakarppa H, Koskinen R, Liippo K, Surcel HM, Leinonen M, et al: Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. Epidemiol Infect. 1997, 118 (2): 155-164. 10.1017/S095026889600725X.CrossRefPubMedPubMedCentral
9.
go back to reference Lieberman D, Ben-Yaakov M, Lazarovich Z, Ohana B, Boldur I: Chlamydia pneumoniae Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Analysis of 250 Hospitalizations. Eur. J. Clin. Microbiol. Infect. Dis. 2001, 20: 698-704. 10.1007/s100960100596. Ref Type: GenericCrossRefPubMed Lieberman D, Ben-Yaakov M, Lazarovich Z, Ohana B, Boldur I: Chlamydia pneumoniae Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Analysis of 250 Hospitalizations. Eur. J. Clin. Microbiol. Infect. Dis. 2001, 20: 698-704. 10.1007/s100960100596. Ref Type: GenericCrossRefPubMed
10.
go back to reference Tompkins LS, Schachter J, Boman J, Chernesky MA, Dowell S, Gaydos CA, et al: Collaborative multidisciplinary workshop report: detection, culture, serology, and antimicrobial susceptibility testing of Chlamydia pneumoniae. J Infect Dis. 2000, 181 (Suppl 3): S460-S461. 10.1086/315599.CrossRefPubMed Tompkins LS, Schachter J, Boman J, Chernesky MA, Dowell S, Gaydos CA, et al: Collaborative multidisciplinary workshop report: detection, culture, serology, and antimicrobial susceptibility testing of Chlamydia pneumoniae. J Infect Dis. 2000, 181 (Suppl 3): S460-S461. 10.1086/315599.CrossRefPubMed
11.
go back to reference Wu L, Skinner SJ, Lambie N, Vuletic JC, Blasi F, Black PN: Immunohistochemical staining for Chlamydia pneumoniae is increased in lung tissue from subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000, 162 (3 Pt 1): 1148-1151.CrossRefPubMed Wu L, Skinner SJ, Lambie N, Vuletic JC, Blasi F, Black PN: Immunohistochemical staining for Chlamydia pneumoniae is increased in lung tissue from subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000, 162 (3 Pt 1): 1148-1151.CrossRefPubMed
12.
go back to reference Smieja M, Chong S, Natarajan M, Petrich A, Rainen L, Mahony JB: Circulating Nucleic Acids of Chlamydia pneumoniae and Cytomegalovirus in Patients Undergoing Coronary Angiography. J Clin Microbiol. 2001, 39 (2): 596-600. 10.1128/JCM.39.2.596-600.2001.CrossRefPubMedPubMedCentral Smieja M, Chong S, Natarajan M, Petrich A, Rainen L, Mahony JB: Circulating Nucleic Acids of Chlamydia pneumoniae and Cytomegalovirus in Patients Undergoing Coronary Angiography. J Clin Microbiol. 2001, 39 (2): 596-600. 10.1128/JCM.39.2.596-600.2001.CrossRefPubMedPubMedCentral
13.
go back to reference Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, et al: Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996, 154 (2 Pt 1): 308-317.CrossRefPubMed Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, et al: Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996, 154 (2 Pt 1): 308-317.CrossRefPubMed
14.
15.
go back to reference Smieja M, Mahony JB, Goldsmith CH, Chong S, Petrich A, Chernesky M: Replicate PCR Testing and Probit Analysis for Detection and Quantitation of Chlamydia pneumoniae in Clinical Specimens. J Clin Microbiol. 2001, 39 (5): 1796-1801. 10.1128/JCM.39.5.1796-1801.2001.CrossRefPubMedPubMedCentral Smieja M, Mahony JB, Goldsmith CH, Chong S, Petrich A, Chernesky M: Replicate PCR Testing and Probit Analysis for Detection and Quantitation of Chlamydia pneumoniae in Clinical Specimens. J Clin Microbiol. 2001, 39 (5): 1796-1801. 10.1128/JCM.39.5.1796-1801.2001.CrossRefPubMedPubMedCentral
16.
go back to reference Hahn DL, Golubjatnikov R: Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscler Thromb. 1992, 12 (8): 945-947.CrossRefPubMed Hahn DL, Golubjatnikov R: Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscler Thromb. 1992, 12 (8): 945-947.CrossRefPubMed
17.
go back to reference Von Hertzen L, Kaprio J, Koskenvuo M, Isoaho R, Saikku P: Humoral immune response to Chlamydia pneumoniae in twin discordant for smoking. J Intern Med. 1998, 244 (3): 227-234.PubMed Von Hertzen L, Kaprio J, Koskenvuo M, Isoaho R, Saikku P: Humoral immune response to Chlamydia pneumoniae in twin discordant for smoking. J Intern Med. 1998, 244 (3): 227-234.PubMed
18.
go back to reference Karvonen M, Tuomilehto J, Pitkaniemi J, Naukkarinen A, Saikku P: Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol. 1994, 23 (6): 1315-1321.CrossRefPubMed Karvonen M, Tuomilehto J, Pitkaniemi J, Naukkarinen A, Saikku P: Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol. 1994, 23 (6): 1315-1321.CrossRefPubMed
Metadata
Title
Smoking, season, and detection of chlamydia pneumoniaeDNA in clinically stable COPD patients
Authors
Marek Smieja
Richard Leigh
Astrid Petrich
Sylvia Chong
Dennis Kamada
Frederick E Hargreave
Charles H Goldsmith
Max Chernesky
James B Mahony
Publication date
01-12-2002
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2002
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-2-12

Other articles of this Issue 1/2002

BMC Infectious Diseases 1/2002 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine